DIGITAL DOCTOR 2023

HEALTH TRACKER SURVEY | GLOBAL SUMMARY $\bullet \bullet \bullet$

Welcome to Digital Doctor 2023!

Running since 2015, Ipsos Digital Doctor provides a comprehensive overview of digital behaviour and future trends among Doctors.

Including, for the first-time, speciality comparisons between the view of PCPs and paediatricians, oncologists, and neurologists.

Some of the key trends in 2023 include:

- 1. Patient empowerment featuring at the centre of connected healthcare solutions, despite it also being seen as a threat
- 2. A shift in remote engagement points to a new post-pandemic "normal" for telehealth
- 3. Opportunities to drive adoption of Artificial Intelligence and Digital Therapeutics
- 4. A move to an omnichannel reality, requiring a mind shift towards a more consumer centric model
- 5. A drive towards a more sustainable and equitable future



Reena Sooch

Global Head of Digital & Connected Health

Reena.Sooch@lpsos.com



Matilda Pateraki Associate Director Matilda.Pateraki@Ipsos.com



The tech trends influencing doctors



Generative Artificial Intelligence for Health, to drive clinical decision making



Rise of Clinical and Patient influencers on social media



Patient generated health data for personalised health services



At home health and monitoring services



TechQuity for better design and deployment of health tech solutions



Clearer reimbursement pathways + evidence for patient apps to facilitate inclusion within healthcare systems



Sample & Methodology





Markets covered and screening criteria

3,428 healthcare professionals (HCPs) across 20 markets

For respondents to qualify they had to:

- Have 2-35 years experience in current role
- Be more than 25 years old
- Paediatricians (Paeds) to recommend/ prescribe/ administer vaccines

Market	PCPs	Paeds	Oncs	Neuros
UK	100	70	61	60
France	100	70	60	60
Italy	100	70	60	60
Spain	100	71	60	60
Germany	100	70	60	60
USA	200	72	60	60
Turkey	100	50		
India	150	50		
China	151	71		
Japan	100	71		
South Korea	50	50		
Vietnam	50	50		
Australia	51	40		
Brazil	100	50		
Belgium	50			
Netherlands	50			
Ireland	50			
Canada	100			
Algeria	100			
Hong Kong S.A.R.	50			

Fieldwork took place between October 2022 – March 2023



Although patient empowerment is seen at the centre of connected healthcare solutions it is also seen as a threat A patient centric benefit is evident; HCPs realise the benefits of digital health are serving the purpose of patient empowerment Agreement with statements (Top 2 Box*)

77%

Agree that with Connected Health Devices (CHDs) it feels easier for patients to understand their own health and health conditions

71%

Agree that with CHDs it has become easier to identify symptoms and take preventative measures



Agree that CHDs allow patients to have more effective conversations with their HCP/nurse




Source: Q6. Please indicate how much you agree or disagree with the following statements in relation to outcomes of using connected health devices or tools? Q7. Now thinking about your own patients. Using the scale below, please indicate how much you agree or disagree with the following statements? **Base:** All respondents (n= 3,428)

*Results shown based on Top 2 Box (1-5 on a scale where 1 = Completely disagree and 5 = Completely agree)



Consensus among Specialists and PCPs on the role of digital health to drive greater patient empowerment

Agreement with statements (Top 2 Box*) – Per specialty



Source: Q6. Please indicate how much you agree or disagree with the following statements in relation to outcomes of using connected health devices or tools? Q7. Now thinking about your own patients. Using the scale below, please indicate how much you agree or disagree with the following statements? Base: All respondents n= Total (n=3428), PCPs (n=1852), Paeds (n=855), Oncologists (n=361), Neurologists (n=360)

*Results shown based on Top 2 Box (1-5 on a scale where 1 = Completely disagree and 5 = Completely agree)



This empowerment comes at a cost with HCPs expressing concerns around patients possibly misinterpreting data or self-diagnosing with the absence of HCPs

Two of the greatest concerns expressed amongst HCPs around using CHDs are:



Believe patients may misinterpret data

52%

Are worried about the potential to cause patients to selfdiagnose/self-manage without physician supervision




Source: Q9. What concerns, if any, do you have about the use of connected health devices and tools? **Base:** All respondents (n= 3,428)

Results shown based on % of HCPs selecting each statement



Paediatricians express a higher concern around patients misinterpreting the data compared to the other specialties; whereas Oncologists are less worried about patients self-diagnosing themselves



10 © IPSOS | DIGITAL DOCTOR HEALTH TRACKER SURVEY | MAR 23 | VERSION 1 | PUBLIC

Base: All respondents n= Total (n=3428), PCPs (n=1852), Paeds (n=855), Oncologists (n=361), Neurologists (n=360)

Source: Q9. What concerns, if any, do you have about the use of connected health devices and tools?

Higher/lower than other specialty
Results shown based on % of HCPs selecting each statement



It is clear that Telehealth is here to stay: A shift in remote engagement points to a new post-pandemic "normal" for telehealth




5



Telehealth has become now a reality and an integral part of Healthcare for four in 10 HCPs, globally. Increasing significantly vs. Pre-COVID-19

% currently using telehealth solutions




Base: All respondents in W1 (n= 1,268), W2 (n= 1,454), W3 (n= 3,428)



However, key challenges remain around ability to accurately diagnose conditions remotely and HCPs are worried about their ability to provide good care

Telehealth challenges



Source: Q13J. Please rank the below statements in order of the degree of challenge they pose, if any, for the implementation of telehealth solutions from your perspective? **Base:** W3'23: All respondents (n= 3,428)



Opportunity exists to further drive adoption of Artificial Intelligence (AI) and Digital Therapeutics (DTx); but there is still work to be done



46%

Agree* that they are excited about the role of Artificial Intelligence in the future of healthcare

*Top 2 Box: On a scale of 1-7, where 1 is 'completely disagree' and 7 is 'completely agree

Source: Q3. On a scale of 1 to 7, where 1 is 'completely disagree' and 7 is 'completely agree', please indicate the extent you agree or disagree with the following statements relating to connected health devices and digital activities. **Base:** All respondents (n= 3.428)




5



Although excitement is seen across specialties, Oncologists and Neurologists claim to be more knowledgeable around Al compared to PCPs & Paediatricians

% selected 'Know a lot' about Al

Artificial Intelligence (AI)




Source: Q1. To what extent are you aware or not aware of the following technologies and solutions in relation to healthcare? Base: All respondents n= Total (n=3428), PCPs (n=1852), Paeds (n=855), Oncologists (n=361), Neurologists (n=360)

▲▼ Higher/lower than other specialty



HCPs see the benefits of AI especially around automation and improvements in diagnosis




Source: Q21. Which of the following do you believe are the main benefits of artificial intelligence solutions, if any? **Base:** All respondents (n= 3,428)

Results shown based on % of HCPs selecting each statement




Around a third are aware of the definition of Digital Therapeutics (DTx), however, recommendation and prescription levels remain low

Source: Q14. Were you previously aware of this definition? Q15. Regarding digital therapeutics, have you done either of the following? **Base:** All respondents (n= 3,428)



Not having enough training on how to use DTx as well as a belief that they lack efficacy and sufficient clinical evidence are the main issues with DTx


Agreement with statements (Top 2 Box*)





The multichannel landscape: communicating with HCPs

Ecosystem of physical and digital channels included in our survey



Source: Q10. Which of the following sources of information, if any, have you used in the last 3 months to obtain medical information to support your everyday clinical practice? **Base:** All respondents (n= 3,428)




An omnichannel reality is becoming evident, however, a mind shift towards a more consumer centric model is required



WhatsApp seems to be the main platform HCPs will interact with for professional reasons; around a third will also use YouTube, LinkedIn and Facebook

Global usage of Social Media platforms




Results shown based on % of HCPs selecting each statement



Source: Q12b. Which of the following social media platforms do you use, if any, for professional reasons? *Base:* All respondents Total (n= 3,428)

HCPs most typically direct patients to non-pharma sites offering lifestyle advice and to other online resources

In the past year I have recommended to my patients...



Source: Q5 In the past year, which of the following, if any, have you recommended for your patients? Base: W3'23: All respondents (n=3,428) Q5a Could you please provide us with more details around the specific sources which you recommend to patients? Base: W3'23: All respondents who have recommended a source to their patients (n=2,708)

Specific sources recommended

"Self-help groups are really good, e.g. MS, rare diseases, etc. Websites from certain pharma companies for certain illnesses, e.g. diabetes, migraine, etc." **PCP, Germany**

"We are mostly giving out leaflets and booklets provided by the pharma companies for the specific treatment options. Mostly we use digital MS platforms to monitor patients." **Neuro, UK**

"I direct patients to CDC's" website cdc.gov for vaccine information. I direct patients to drugs.com for medication information. I direct patients to WebMD and Mayoclinic.org for patient information handout-type disease information." **PCP, USA**

*Centres for Disease Control and Prevention

Results shown based on % of HCPs selecting each statement



Driving towards a more sustainable and equitable future

lpsos

Inability for a full assessment from HCPs and poor broadband issues from patients are seen as main barriers of using / accessing Telehealth

Perceptions around remote consultations and TechQuity



Although 72%*

agree that CHDs facilitate greater access to healthcare for patients who may not have easy access

***Results shown based on Top 2 Box** (1-5 on a scale where 1 = Completely disagree and 5 = Completely agree)



The main barriers for patients according to HCPs is health & tech literacy / access**:

- **44%** believe patients have difficulty describing their situation accurately
- **44%** believe patients have poor broadband issues
- **40%** believe patients don't always have the right equipment to participate


**Results shown based on % of HCPs selecting each statement

Source: Q6. Please indicate how much you agree or disagree with the following statements in relation to outcomes of using connected health devices or tools? Q13h. What are or could be the barriers, if any, that would prevent patients using telehealth solutions? Base: All respondents (n= 3,428)



When thinking about the future of in-home healthcare, HCPs are more positive about in-home self monitoring tools versus in-home virtual wards

Agreement with statements (Top 2 Box*)




Source: Q3. On a scale of 1 to 7, where 1 is completely disagree and 7 is completely agree, please indicate the extent you agree or disagree with the following statements relating to connected health devices and digital activities. Base: W3'23: All respondents (n=3,428)





Feelings (positive vs. negative) are evenly balanced about the entrance of tech companies into the digital and connected health field

When I think about the entrance of tech companies into the digital and connected health field I am...



Q9c. How do you feel about the entrance of tech companies like Amazon, Google etc. into the digital and connected health field? Base: W3'23: All respondents (n=3,428)


Overall:

62% of HCPs express at least one positive
54% of HCPs express at least one negative



HCPs have a stronger preference for biopharma/ medical device companies to develop digital and CHDs versus technology companies

Preference of technology over biopharma companies



Preference for technology companies

No preference

Preference for biopharmaceutical/ medical device companies

Q9b. Please answer on the scale below if you would prefer digital and connected health devices developed by technology companies or biopharmaceutical/ medical device companies. Base: W3'23: All respondents (n=3,428)



Ipsos's Standards & Accreditations

Ipsos's standards & accreditations provide our clients with the peace of mind that they can always depend on us to deliver reliable, sustainable findings. Moreover, our focus on quality and continuous improvement means we have embedded a 'right first time' approach throughout our organisation.



ISO 20252 – is the international market research specific standard that supersedes BS 7911 / MRQSA & incorporates IQCS (Interviewer Quality Control Scheme); it covers the 5 stages of a Market Research project. Ipsos UK was the first company in the world to gain this accreditation.



MRS Company Partnership – By being an MRS Company Partner, Ipsos UK endorse and support the core MRS brand values of professionalism, research excellence and business effectiveness, and commit to comply with the MRS Code of Conduct throughout the organisation & we were the first company to sign our organisation up to the requirements & self regulation of the MRS Code; more than 350 companies have followed our lead.



ISO 9001 – International general company standard with a focus on continual improvement through quality management systems. In 1994 we became one of the early adopters of the ISO 9001 business standard.



ISO 27001 – International standard for information security designed to ensure the selection of adequate and proportionate security controls. Ipsos UK was the first research company in the UK to be awarded this in August 2008.



The UK General Data Protection Regulation (UK GDPR) & the UK Data Protection Act 2018 (DPA) – Ipsos UK is required to comply with the UK General Data Protection Regulation and the UK Data Protection Act; it covers the processing of personal data and the protection of privacy.

Ipsos UK is an active member of EphMRA and BHBIA.



HMG Cyber Essentials – A government backed and key deliverable of the UK's National Cyber Security Programme. Ipsos UK was assessment validated for certification in 2016. Cyber Essentials defines a set of controls which, when properly implemented, provide organisations with basic protection from the most prevalent forms of threat coming from the internet.



Fair Data – Ipsos UK is signed up as a 'Fair Data' Company by agreeing to adhere to ten core principles. The principles support and complement other standards such as ISOs, and the requirements of Data Protection legislation.

This work was carried out in accordance with the requirements of the international quality standard for market research, ISO 20252 and with the Ipsos UK Terms and Conditions



Contact us:



Matilda Pateraki

Associate Director

Matilda.Pateraki@Ipsos.com

